Finn
MRK Pharmaceuticals · Large cap · Oncology · Vaccines · Thesis updated November 1, 2026

Merck balances massive new drug launches against accelerating patent cliffs

01 Running thesis

A race between new launches and old cliffs

Merck is executing a portfolio transition, and the bridge to its future is taking shape. KEYTRUDA remains the core profit engine, while WINREVAIR is proving to be a massive cardiovascular growth driver with $694 million in Q3 2026 sales. The recent launch of LIPFENDRA adds another major asset, seeing over 11,000 prescriptions early on.

The challenge is the sheer size of the revenue gap the company must fill. Multiple generic versions of BRIDION have now entered the market. Combined with losses for JANUVIA and Adempas, management expects over $2 billion in revenue headwinds for 2027.

The bull case is strengthening because Merck is successfully defending its core with KEYTRUDA QLEX and building new revenue streams fast enough to offset older product losses. The company is also heavily augmenting its pipeline via multi-billion dollar acquisitions like Terns and Cidara.

The bear case centers on near-term margin pressure and execution risks. If LIPFENDRA adoption stalls or if international pricing laws compress margins, the company could struggle. A new Dutch injunction against KEYTRUDA QLEX also highlights the fragility of the transition in Europe.

Oct 2026→Q3 2026 earnings showed strong launches for WINREVAIR and LIPFENDRA, but management warned of over $2 billion in exclusivity headwinds for 2027 and noted a European IP injunction hitting KEYTRUDA QLEX.
Aug 2026→The Q2 2026 10-Q highlighted $16 billion in acquisitions, including Terns and Cidara, to bridge the revenue gap. It also noted new pricing pressures from Germany's GKV-BStabG legislation starting in 2027.
Aug 2026▲The Q2 2026 report materially derisked the near-term transition. Merck secured FDA approval for LIPFENDRA, WINREVAIR sales grew to $588 million, and GARDASIL sales stabilized globally.
May 2026→Q1 2026 confirmed both sides of the transition. WINREVAIR reached $525 million in sales, while Merck said GARDASIL revenue from China in 2026 should be immaterial and repeated the mid-2026 exclusivity losses for JANUVIA, JANUMET, and BRIDION.
Apr 2026▲The earnings call made the launch story more believable. WINREVAIR posted $525 million in global sales, and WELIREG rose to $199 million, partly offsetting the weak GARDASIL update.
Feb 2026▼The 2025 10-K made the GARDASIL problem worse, with full-year sales down 39 percent and China shipments still paused. It also gave clear 2026 timing for JANUVIA and BRIDION exclusivity losses.
Feb 2026→Management pointed to KEYTRUDA peak sales of about $35 billion by 2028, which helped the bull case. That was balanced by a 35 percent Q4 drop in GARDASIL sales and 2026 EPS guidance affected by a large Cidara acquisition charge.
Nov 2025▲The FDA approval of Keytruda Qlex helped Merck defend its core KEYTRUDA franchise. The same filing kept pressure on the thesis by confirming no further GARDASIL shipments to China for 2025 and a July 2026 BRIDION exclusivity loss.
02 Business model

Science, sales, and heavy reinvestment

Merck discovers, develops, makes, and sells medicines and vaccines. Most sales come from human health products sold to drug wholesalers, retailers, hospitals, governments, and health plans. A smaller but growing Animal Health business sells medicines, vaccines, and monitoring tools for livestock and pets.

The model works best when Merck owns protected drugs with strong demand. Patents and regulatory exclusivity help protect pricing and market share for a time. When that protection ends, generic or competing products can take a large share quickly, as seen with BRIDION.

Merck is actively preparing for that cycle. It deployed $16 billion in the first half of 2026 to acquire Terns and Cidara, aiming to augment its pipeline. Its 2025 Restructuring Program is also meant to generate about $3.0 billion in annual savings by the end of 2027, which the company is reinvesting into these new growth areas.

That plan adds discipline, but it also shows the pressure. Merck must keep funding expensive research while replacing revenue from older products and handling new international pricing pressures, like Germany's recent health care reform law.

03 Product portfolio

The drugs that matter most

Cash cow

KEYTRUDA

KEYTRUDA is Merck's lead cancer drug and the main profit engine. Management has framed the drug as central to growth through its peak years.

Option

Keytruda Qlex

Keytruda Qlex is the subcutaneous version of KEYTRUDA. It generated $830 million in Q3 2026 and helps defend the franchise against future competition.

Growth engine

WINREVAIR

WINREVAIR treats pulmonary arterial hypertension. Sales reached $694 million in Q3 2026, making it the clearest new launch success.

Growth engine

LIPFENDRA

LIPFENDRA is an oral PCSK9 inhibitor to help reduce LDL cholesterol. It saw over 11,000 early prescriptions and serves as a massive new primary care asset.

Cash cow

GARDASIL and GARDASIL 9

GARDASIL is Merck's HPV vaccine franchise. It stabilized globally in 2026 after suffering sharp demand drops in China.

Cash cow

JANUVIA and JANUMET

JANUVIA and JANUMET are diabetes products now facing generic competition. They lost U.S. market exclusivity in May 2026.

Cash cow

BRIDION

BRIDION is used to reverse certain anesthesia effects after surgery. Multiple generic competitors have now entered the market, eroding sales.

Steady

Animal Health

Animal Health sells veterinary medicines, vaccines, and health management tools. It continues to deliver solid sales growth across livestock and companion animal portfolios.

04 Business segments

Mostly human health

Pharmaceutical89%modest
Animal Health11%growing fast

Mix is based on recent reportable segment sales. The human health division drives the vast majority of revenue, heavily weighted toward oncology and cardiometabolic drugs.

05 Risk factors

What could break the story

The 2027 revenue cliff

High impact · High odds

Management guided to over $2 billion in revenue headwinds for 2027 from older products. With multiple generic competitors now in the market for BRIDION, the revenue hit will be substantial and immediate.

We watchQuarterly sales declines for BRIDION, JANUVIA, and Adempas.

European IP injunctions on KEYTRUDA QLEX

Medium impact · Medium odds

A Dutch intellectual property ruling temporarily halted KEYTRUDA QLEX supply in several key European markets. If the injunction holds or expands, it could slow the critical transition away from the original KEYTRUDA formulation.

We watchLegal updates on the Dutch injunction and European QLEX sales figures.

LIPFENDRA adoption stalls

High impact · Medium odds

The bull case requires LIPFENDRA to scale into a massive growth driver. If primary care physician inertia and access hurdles limit its uptake against entrenched generic statins and injectable PCSK9s, Merck will lose a key growth pillar.

We watchInitial launch metrics, formulary placement, and quarterly LIPFENDRA prescription volumes.

Pricing pressure expands

Medium impact · High odds

The Inflation Reduction Act subjects JANUVIA, JANUMET, and LENVIMA to U.S. government price setting. Internationally, Germany passed the GKV-BStabG law, which will exert significant downward pressure on sales starting in 2027. Lower prices reduce margins even when demand stays healthy.

We watchCMS drug price setting lists and Merck commentary on European net pricing.

Pipeline spending fails to pay off

High impact · Medium odds

Merck is spending heavily to acquire future products, deploying $16 billion in the first half of 2026 for Terns and Cidara. If late-stage data disappoints, the company may spend heavily without filling the late-decade revenue gap.

We watchPhase III readouts, regulatory decisions, and updates on acquired assets like MK-4208 and MK-1406.
06 Quick answers

In one breath

What does Merck make?

Merck makes prescription medicines, vaccines, and animal health products. Its most important product is KEYTRUDA, a cancer drug, but it also sells vaccines like GARDASIL and newer medicines like WINREVAIR and LIPFENDRA.

What is Merck doing about the patent cliffs?

The company is launching new drugs like WINREVAIR and LIPFENDRA. It is also buying other companies, spending $16 billion in early 2026 to acquire Terns and Cidara for their drug pipelines.

Why do WINREVAIR and LIPFENDRA matter so much?

They are Merck's clearest new growth drivers to replace older drugs. WINREVAIR reached $694 million in Q3 2026 sales, and LIPFENDRA gives the company a massive new primary care asset.

What is the main debate on Merck stock?

The debate is whether Merck can replace older product sales fast enough. Bulls point to KEYTRUDA QLEX, new drug launches, and recent acquisitions. Bears point to mid-2026 generic losses and international pricing pressures.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Merck Q3 2026 earnings transcript
  2. Merck Q2 2026 Form 10-Q
  3. Merck Q2 2026 earnings transcript
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Merck & Co., Inc. in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today